期刊文献+

P-糖蛋白表达与原发性肝癌合并门静脉癌栓患者术后辅助化疗效果的相关性研究 被引量:2

Correlation between the expression of P-gp and efficacy of chemotherapy postoperation in hepatocellular carcinoma patients with tumor thrombi in major portal vein
原文传递
导出
摘要 目的研究P-糖蛋白(P-gp)表达与原发性肝细胞癌合并门静脉癌栓患者表达情况与临床化疗效果之间的关系。方法收集术后接受化疗的29例原发性肝细胞癌合并门静脉癌栓患者的石蜡块,构建组织芯片。采用免疫组化染色技术,检测P-gp蛋白的表达情况。根据P-gp蛋白表达强弱分为耐药组和非耐药组,进行生存分析。结果 P-gp蛋白表达的阳性率为75.86%(22/29)。中位无瘤生存期在耐药组(20例)与非耐药组(9例)间有显著差别。多因素Cox回归分析显示P-gp表达情况为无瘤生存期的独立影响因子。结论 P-gp的强表达是导致肝癌耐药、化疗效果欠佳的原因之一,P-gp有可能作为临床筛选化疗患者的指标。 Objective To investigate the expression of P-glycoprotein (P-gp) and its correlation to chemotherapeutic efficacy in hepatoeellular carcinoma (HCC) with tumor thrombi in major portal vein. Methods Twenty-nine patients of HCC with tumor thrombi in major portal vein following hepatectomy and thrombectomy were enrolled in this study, all the patients received immunochemotherapy postperatively. Specimens embedded in paraffin were collected for the construction of tissue microarrays. P-gp protein were visualized by immunohistochemical staining using Monoclonal antibodies JSB-1. The patients were divided into chemotherapy sensitive and resistant groups according to the staining grade. The intensity ≥ (++) were considered resistant to chemotherapy. Survival time was compared between the two groups and prognostic factors were identified using Cox proportional hazards model. Results The positive rate of P-gp was 75.86% (22/29). Medium tumor-free survival time showed significant differences between two groups. Multivariate analysis revealed that the expression grade of P-gp was independent prognostic factor for tumor-free survival time. Conclusion In HCC with tumor thrombi in major portal vein, the overexpression of P-gp is one of the major reason for resistance to chemotherapy, detection of which will be helpful in chemotherapy decision making.
出处 《中华普通外科学文献(电子版)》 2013年第5期14-16,35,共4页 Chinese Archives of General Surgery(Electronic Edition)
关键词 P-糖蛋白 肝细胞癌 癌栓 门静脉 化疗 P-glycoprotein Hepatocellular carcinoma Tumor thrombi Portal vein Chemotherapy
  • 相关文献

参考文献11

  • 1Liang LJ, Hu WJ, Yin XY, etal. Adjuvant intraportal venous chemotherapy for patients with hepatocellular carcinoma and portal vein tumor thrombi following hepatectomy plus portal tbrombectomy. WJS, 2008, 32(4): 627-631.
  • 2Breuninger LM, Paul S, Gaughan K, et al. Expression of mulfidrug resistance-associated protein in NIH/3T3 cells confers muhidrug resistance associated with increased drug efflux and altered intraeellular drug distribution. Cancer Res, 1995, 55(22): 5342- 5347.
  • 3彭靖,张玉胜,梁志鹏,高焱明.多药耐药蛋白、P-糖蛋白及DNA拓扑异构酶Ⅱ与胰腺癌化疗耐药的相关影响因素分析[J].中华普通外科学文献(电子版),2012,6(4):11-14. 被引量:5
  • 4杨锡贵,贾丽雅,魏玲,左文述,宋恕平.恶性淋巴瘤mdr1和MRP mRNA及P-gp表达水平与化疗疗效的相关研究[J].中华医学杂志,2002,82(17):1177-1179. 被引量:13
  • 5Kelley D J, Pavelic ZP, Gapany M, et al. Detection of P-glycoprotein in squamous cell carcinomas of the head and neck. Arch Otolaryngol Head Neck Surg, 1993, 119(4): 411-414.
  • 6Baldini N, Scotlandi K, Barbanti-Brodano G, et al. Expression of P-glycoprotein in high-grade osteosareomas in relation to clinical outcome. N Engl J Med, 1995, 333(21):1380-1385.
  • 7Ng IO, Liu CL, Fan ST, et al. Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response. Am J Clin Pathol, 2000, 113(3): 355-363.
  • 8Chou YY, Cheng AL, Hsu HC. Expression of P-glyeoprotein and p53 in advanced hepatoeellular carcinoma treated by single agent chemotherapy: clinical correlation. J Gastroenterol Hepatol, 1997, 12(8): 569-575.
  • 9Itsubo M, Ishikawa T, Toda G, et al. Immunohistoehemieal study of expression and cellular localization of the muhidrug resistance gene product P-glycoprotein in primary liver carcinoma. Cancer, 1994, 73(2): 298-303.
  • 10Cordon-Cardo C, O'Brien JP, Boecia J, et al. Expression of the muhidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem, 1990, 38(9): 1277-1287.

二级参考文献11

  • 1刘炳仁,杨纯正,栾凤君,熊冬生,刘瑞林,卞寿庚,薛艳萍,郝玉书.用逆转录-多聚酶链反应检测白血病患者多药耐药基因的表达[J].中华血液学杂志,1995,16(2):65-68. 被引量:27
  • 2刘立新,李中德,孙燕.恶性淋巴瘤患者多药耐药的研究[J].中华血液学杂志,1995,16(6):309-311. 被引量:18
  • 3徐近,李骥,龙江,虞先浚,金忱,傅德良,倪泉兴.胰腺癌P-gp的表达及其临床相关影响因素的分析[J].外科理论与实践,2007,12(3):249-252. 被引量:1
  • 4Ridwelski K, Meyer F, Ebert M, et al. Prognostic parameters determining survival in pancreatic carcinoma after palliative treatment. Dig Dis, 2001,19( 1 ) : 85-92.
  • 5Yabuki N, SasaD OH, Kata K, et al. Immunohistochemical study of DNA topoisomerase 1I in human gastric disorders. Am J Pathol, 1996, 149(3) :977-1008.
  • 6Arancia G, Molinari A, Calcabrini A, et al. Intracellular P-glycoprotein in muhidrug resistant tumor cells. Ital J Anat Embryol, 2001,106(2 Suppl 1) :59-68.
  • 7Ruefli AA, Tainton KM, Darcy PK, et al. P-glycoprotein inhibits caspase-8 activation but not formation of the death inducing signal complex (disc) following Fas hgation. Cell Death Differ, 2002,9 ( 11 ) : 1266-1272.
  • 8Kato A, Miyazaki M, Ambiru S, et al. Muhidrug resistance gene (MDR-1 ) expression as a useful prognostic factor in patients with human hepatocellular carcinoma after surgical resection. J Surg Oncol, 2001,78(2) : 110-115.
  • 9Lu Z, Kleff J, Shrikhande S, et al. Expression of the multidrug resistance 1 (MDR1) gene and prognosis in human pancreatic cancer. Pancreas, 2000,21 (3) : 240-247.
  • 10许元富,杨纯正,熊冬生,邵晓枫,王珊,孙云晖,薛艳萍,李维廉.抗Pgp抗体PHMA02在肿瘤临床中的应用研究及预后分析[J].中国肿瘤临床,1999,26(9):645-649. 被引量:8

共引文献16

同被引文献22

  • 1Liver Cancer Study Group of Japan. Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment[J!. Ann Surg, 1990, 211(3): 277-287.
  • 2Fujii T, Takayasu K, Muramatsu Y, et al. Hepatocellular carcinoma with portal tumor thrombus: analysis of factors determining prognosis[J]. Jpn J Clin Oncol, 1993, 23(2): 105-109.
  • 3Ikai I, Arii S, Ichida T, et al. Report of the 16th follow-up survey of primary liver cancer[J]. Hepatol Res, 2005, 32(3): 163-172.
  • 4Llovet JM, Bustamante J, Castells A, et al. Natural hist,3ry of untreated nonsurgieal hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials[J]. Hepatology, 1999, 29(1): 62-67.
  • 5Nies AT, Konig J, Pfannschmidt M, et al. Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma[J]. Int J Cancer, 2001, 94(4): 492-499.
  • 6Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a muhidrug-resistant human lung cancer cell line[J]. Science, 1992, 258(5088): 1650-1654.
  • 7Breuninger LM, Paul S, Gaughan K, et al. Expression of mulLtidrug protein in NIH/3T3 cells confers mtdtidrug resistance associated with increased drug efflux and altered intracellulsr drug distribution [J]. Cancer Res, 1995, 55(22): 5342-5347.
  • 8Nooter K, Westerman AM, Flens M J, et al. Expression of the multidrug resistance-associated protein (MRP) gene in human cancers[J]. Chn Cancer Res, 1995,1(11): 1301-1310.
  • 9Korita PV, Wakai T, Shirai Y, et al. Muhidrug resistance-associated protein 2 determines the efficacy of cisplafin in patients with hepatocellular careinoma[J]. Oncol Rep, 2010, 23(4): 965-972.
  • 10Bonin S1, Pascolo L Croc LS, et al. Gene expression of ABC pro:eins in hepatocellular carcinoma, pefineoplastic tissue, and liver diseaseslJ]. Mol Med, 2002, 8(6): 318-325.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部